APA (7th ed.) Citation

MA, A., CS, M., AJ, N., PJ, P., & JA, M. (2025). Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond. Heart, lung & circulation, 34(10), 995. https://doi.org/10.1016/j.hlc.2025.07.005

Chicago Style (17th ed.) Citation

MA, Allahwala, Marathe CS, Nelson AJ, Psaltis PJ, and Marathe JA. "Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond." Heart, Lung & Circulation 34, no. 10 (2025): 995. https://doi.org/10.1016/j.hlc.2025.07.005.

MLA (9th ed.) Citation

MA, Allahwala, et al. "Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond." Heart, Lung & Circulation, vol. 34, no. 10, 2025, p. 995, https://doi.org/10.1016/j.hlc.2025.07.005.